Achieving high non-viral transfection performance for cell therapy processing

Available to watch now on demand

Cell therapies often involve introduction of genetically transformed cells into a patient. Recently there has been renewed interest in non-viral gene modification for this application as an alternative to lentiviral vectors. Non-viral electroporation utilizing CRISPR-Cas9 is continuing to show improved performance and safety benefits in the area of cell-based immunotherapy. Furthermore, because electroporation is easy and rapid, it can transfect a large number of cells in a short time once optimum electroporation conditions are determined.

During this webinar, we will discuss the Gibco™ CTS™ Xenon™ Electroporation System, which has been developed to deliver reliably high transfection performance in volumes of 1–25 mL in a closed system with improved cell viability and recovery. The programmable interface, process flexibility, sterile single-use consumables and available 21 CFR Part 11 compliance–compatible software upgrade allow the system to seamlessly scale with your cell therapy process from development through clinical manufacturing. The 1 mL electroporation chamber enables efficient process development and scales directly to commercial manufacturing using the 5–25 mL cartridge. This larger volume consumable enables sterile processing and an OPC-UA interface allows connectivity to a 21 CFR Part 11–compliant system.

REGISTER NOWWhat will you learn?Who may this interest?Speaker

What will you learn?

  • Understand how process flexibility and ability to optimize electroporation protocols can assist through the process development phase of a cell therapy program
  • Discuss the typical numbers of cells required for cell therapy process development and manufacturing applications
  • Explore the safety, performance and regulatory advantages of mechanical, non-viral transfection for cell therapy

Who may this interest?

  • Process Scientist
  • Scientist
  • Principal Scientist
  • Research Scientist
  • Research Assistant
  • Process Development Scientist
  • Process Development Manager
  • Principal Investigator
  • Lab Manager
  • Core Facility Manager
  • Process Engineer
  • Director Cell Engineering and Gene Editing
  • Professor


Nektaria Andronikou
Senior R&D Manager
Thermo Fisher Scientific (MD, USA)

Nektaria Andronikou is a Senior R&D Manager for Thermo Fisher Scientific’s Biosciences Division focused on the development and improvement of mechanical based delivery products for use within cell and gene therapy workflows. She currently leads a small team of innovative scientists working with various primary cell models and payload/cargo types, such as CRISPR, mRNA and DNA, to improve non-viral based transfection and delivery. Throughout her time at Thermo Fisher Scientific, Nektaria was an integral member of the cross-functional teams that developed the Lipofectamine 3000, MessengerMAX and Invivofectamine 3.0 transfection reagents. She began her professional career at Ionis Pharmaceuticals (formerly ISIS Pharmaceuticals, CA, USA), as a research associate for the Cardiovascular Drug Discovery program. She received a Bachelor of Science in Biochemistry with a minor in Cellular and Molecular Biology from UCSD (CA, USA). She has been with Thermo Fisher for eleven years and has been dedicated to the understanding and commercialization of improving delivery technologies for clinical, translational and research markets.


In association with